PacBio's (PACB) New Panel to Aid Its Clinical Research Solution

Pacific Biosciences of California PACB, popularly known as PacBio,recently announced the PureTarget repeat expansion panel, a new approach that makes it possible to thoroughly examine 20 genes linked to severe neurological conditions, including difficult-to-sequence genes with tandem repeat expansions, is now possible.

In addition to cutting down on the amount of time required to find disease-causing variations and the methylation signatures that go along with them, the new long-read process can eliminate iterative analysis utilizing outdated technologies.

Price Performance

For the past six months, PACB’s shares have plunged 63.6% against the industry’s rise of 14%. The S&P 500 increased 13.9% in the same time frame.

Zacks Investment Research
Image Source: Zacks Investment Research

More on PureTarget Panel

HiFi sequencing is uniquely capable of comprehensively characterizing the germline and somatic variation of tandem repeats, which cause dozens of neurological diseases. The purpose of the PureTarget repeat expansion panel is to help customers comprehend the foundations of tandem repeats by focusing on repeat expansions.

The panel targets long-read sequencing of pure DNA using a unique methodology. PureTarget libraries provide a comprehensive picture of disease genes such as FMR1, which is likely to save the company’s customers from having to run a second experiment by retaining methylation signatures.

Targeted sequencing is a great way for academics and commercial labs to examine and evaluate the function of genes and gene variations at a reasonable cost. Several severe neurological conditions that affect both adults and children, such as ataxia, Huntington's disease, myotonic dystrophy, amyotrophic lateral sclerosis, frontotemporal dementia, and fragile X disease, are linked to the 20 genes that make up the PureTarget repeat expansion panel.

The recently released Nanobind PanDNA kit is used in the PureTarget Repeat Expansion Panel procedure, which guarantees reliable outcomes tailored for Revio and Sequel IIe customers. On the PacBio Revio sequencing system, customers can multiply up to 48 samples, whereas on the PacBio Sequel IIe sequencing system, they can multiply 24 samples.

PureTarget panel is expected to be available for shipment starting Mar 25, 2024. The company expects that this panel could improve PacBio's commercial possibility by allowing thousands of samples at the largest facilities in the world to be processed quickly and with a streamlined methodology.

Industry Prospects

Per a report by Grand View Research, the global long-read sequencing market size was valued at $455.1 million in 2022 and is expected to grow at 30.92% from 2023 to 2030.

The major factors driving the market growth include the rising prevalence of genetic diseases, such as cancers, as well as chromosomal disorders, the increasing popularity of personalized medicine, and rising technological advancements resulting in the emergence of newer technologies, such as third-generation sequencing.

Notable Developments

In January 2024, PacBio announced PanDNA, a versatile Nanobind DNA extraction kit. With the addition of this new offering, the range of sample types appropriate for long-read sequencing is now greater and includes bacteria, cells, tissue, blood, plant nuclei, and insects.

In October 2023, the company announced the availability of a complete, standardized computational method for HiFi whole genome sequencing (WGS) data analysis, the PacBio WGS Variant Pipeline. This availability aims to significantly strengthen PacBio’s global sequencing business.

Pacific Biosciences of California, Inc. Price

Pacific Biosciences of California, Inc. Price

Pacific Biosciences of California, Inc. price | Pacific Biosciences of California, Inc. Quote

Zacks Rank & Stocks to Consider

PACB carries a Zacks Rank #3 (Hold) at present.

Some better-ranked stocks in the broader medical space are DaVita Inc. DVACardinal Health, Inc. CAH and Cencora, Inc. COR.

DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 12.1%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 35.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.

DaVita’s shares have gained 58.3% compared with the industry’s 18.9% rise in the past year.

Cardinal Health, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 14.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average being 15.6%.

Cardinal Health has gained 51.9% compared with the industry’s 3.2% rise in the past year.

Cencora, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 9.8%. COR’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.7%.

Cencora’s shares have rallied 51.5% compared with the industry’s 3.6% rise in the past year.

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

DaVita Inc. (DVA) : Free Stock Analysis Report

Cardinal Health, Inc. (CAH) : Free Stock Analysis Report

Cencora, Inc. (COR) : Free Stock Analysis Report

Pacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.